{"title":"<i>Akkermansia muciniphila</i> in patients with metabolic dysfunction-associated steatotic liver disease.","authors":"Adina Ioana Mihele, Liviu Lazar","doi":"10.25122/jml-2024-0342","DOIUrl":null,"url":null,"abstract":"<p><p><i>Akkermansia muciniphila</i> (AM), one of the many microbial species residing in the human gut, has been particularly highlighted for its potential beneficial impacts on host metabolism and gut barrier function. This study evaluated the association between AM concentration and metabolic markers among patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASL). The study included a cohort of 122 patients with MASLD, monitored between January 1 and June 30, 2024, at the Venus Vascular Center in Oradea, Romania. Enterotype 2 was predominant in the study population, accounting for over 60% of participants. Correlation analysis revealed no statistically significant association between alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels and AM concentration (ALT: r = -0.147, <i>P</i> = 0.105; AST: r = -0.090, <i>P</i> = 0.325). However, a significant negative linear correlation was determined between gamma-glutamyl transferase (GGT) values and AM concentrations (r = -0.314, <i>P</i> < 0.001) and a moderate, positive correlation between high-density lipoprotein (HDL) values and AM concentration (r = 0.307, <i>P</i> < 0.001). Glycemia showed a weak negative correlation with AM concentration (r = -0.262, <i>P</i> = 0.003). The improvement of liver markers (AST, ALT), even in the absence of correlation with AM concentration, and the negative correlation of GGT, a marker for hepatobiliary diseases and metabolic syndrome, suggest the reduction of oxidative stress in MASLD.</p>","PeriodicalId":16386,"journal":{"name":"Journal of Medicine and Life","volume":"17 9","pages":"880-885"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611053/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicine and Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25122/jml-2024-0342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Akkermansia muciniphila (AM), one of the many microbial species residing in the human gut, has been particularly highlighted for its potential beneficial impacts on host metabolism and gut barrier function. This study evaluated the association between AM concentration and metabolic markers among patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASL). The study included a cohort of 122 patients with MASLD, monitored between January 1 and June 30, 2024, at the Venus Vascular Center in Oradea, Romania. Enterotype 2 was predominant in the study population, accounting for over 60% of participants. Correlation analysis revealed no statistically significant association between alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels and AM concentration (ALT: r = -0.147, P = 0.105; AST: r = -0.090, P = 0.325). However, a significant negative linear correlation was determined between gamma-glutamyl transferase (GGT) values and AM concentrations (r = -0.314, P < 0.001) and a moderate, positive correlation between high-density lipoprotein (HDL) values and AM concentration (r = 0.307, P < 0.001). Glycemia showed a weak negative correlation with AM concentration (r = -0.262, P = 0.003). The improvement of liver markers (AST, ALT), even in the absence of correlation with AM concentration, and the negative correlation of GGT, a marker for hepatobiliary diseases and metabolic syndrome, suggest the reduction of oxidative stress in MASLD.
期刊介绍:
The Journal of Medicine and Life publishes peer-reviewed articles from various fields of medicine and life sciences, including original research, systematic reviews, special reports, case presentations, major medical breakthroughs and letters to the editor. The Journal focuses on current matters that lie at the intersection of biomedical science and clinical practice and strives to present this information to inform health care delivery and improve patient outcomes. Papers addressing topics such as neuroprotection, neurorehabilitation, neuroplasticity, and neuroregeneration are particularly encouraged, as part of the Journal''s continuous interest in neuroscience research. The Editorial Board of the Journal of Medicine and Life is open to consider manuscripts from all levels of research and areas of biological sciences, including fundamental, experimental or clinical research and matters of public health. As part of our pledge to promote an educational and community-building environment, our issues feature sections designated to informing our readers regarding exciting international congresses, teaching courses and relevant institutional-level events.